D
Dennis C. Sgroi
Researcher at Harvard University
Publications - 222
Citations - 31566
Dennis C. Sgroi is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 80, co-authored 209 publications receiving 29207 citations. Previous affiliations of Dennis C. Sgroi include Joslin Diabetes Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Akira Orimo,Piyush Gupta,Dennis C. Sgroi,Fernando Arenzana-Seisdedos,Thierry Delaunay,Rizwan Naeem,Vincent J. Carey,Andrea L. Richardson,Robert A. Weinberg +8 more
TL;DR: Using a coimplantation tumor xenograft model, it is demonstrated that carcinoma-associated fibroblasts extracted from human breast carcinomas promote the growth of admixed breast carcinoma cells significantly more than do normal mammaries derived from the same patients.
Journal ArticleDOI
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Min Yu,Aditya Bardia,Ben S. Wittner,Shannon L. Stott,Malgorzata E. Smas,David T. Ting,Steven J. Isakoff,Jordan C. Ciciliano,Marissa N. Wells,Ajay Shah,Kyle Concannon,Maria C. Donaldson,Lecia V. Sequist,Elena F. Brachtel,Dennis C. Sgroi,José Baselga,Sridhar Ramaswamy,Mehmet Toner,Daniel A. Haber,Daniel A. Haber,Shyamala Maheswaran +20 more
TL;DR: A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.
Journal ArticleDOI
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji,Kristian Cibulskis,Claudia Rangel-Escareño,Kristin K. Brown,Scott L. Carter,Abbie M. Frederick,Michael S. Lawrence,Andrey Sivachenko,Carrie Sougnez,Lihua Zou,Maria L. Cortes,Juan Carlos Fernández-López,Shouyong Peng,Kristin G. Ardlie,Daniel Auclair,Verónica Bautista-Piña,Fujiko Duke,Joshua M. Francis,Joonil Jung,Antonio Maffuz-Aziz,Robert C. Onofrio,Melissa Parkin,Nam Pho,Valeria Quintanar-Jurado,Alex H. Ramos,Rosa Rebollar-Vega,Sergio Rodriguez-Cuevas,Sandra Romero-Cordoba,Steven E. Schumacher,Steven E. Schumacher,Nicolas Stransky,Kristin Thompson,Laura Uribe-Figueroa,José Baselga,Rameen Beroukhim,Rameen Beroukhim,Kornelia Polyak,Dennis C. Sgroi,Andrea L. Richardson,Gerardo Jimenez-Sanchez,Eric S. Lander,Eric S. Lander,Eric S. Lander,Stacey Gabriel,Levi A. Garraway,Levi A. Garraway,Todd R. Golub,Jorge Melendez-Zajgla,Alex Toker,Gad Getz,Alfredo Hidalgo-Miranda,Matthew Meyerson,Matthew Meyerson +52 more
TL;DR: Recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1 are confirmed and a recurrent MAGI3–AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression is identified.
Journal ArticleDOI
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
Xiao Jun Ma,Zuncai Wang,Paula D. Ryan,Steven J. Isakoff,Anne Barmettler,Andrew P. Fuller,Beth Muir,Gayatry Mohapatra,Ranelle C. Salunga,J. Todd Tuggle,Yen Tran,Diem Tran,Ana Tassin,Paul Amon,Wilson Wang,Wei Wang,Edward Enright,Kimberly Stecker,Eden Estepa-Sabal,Barbara L. Smith,Jerry Younger,Ulysses J. Balis,James S. Michaelson,Atul K. Bhan,Karleen Habin,Thomas M. Baer,Joan S. Brugge,Daniel A. Haber,Mark G. Erlander,Dennis C. Sgroi +29 more
TL;DR: An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers and may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.
Journal ArticleDOI
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver,Andrea L. Richardson,Aron Charles Eklund,Zhigang C. Wang,Zoltan Szallasi,Qiyuan Li,Nicolai Ytterdal Juul,Chee-Onn Leong,Diana Calogrias,Ayodele Buraimoh,Aquila Fatima,Rebecca Gelman,Paula D. Ryan,Nadine Tung,Arcangela De Nicolo,Shridar Ganesan,Alexander Miron,Christian Colin,Dennis C. Sgroi,Leif W. Ellisen,Eric P. Winer,Judy Garber +21 more
TL;DR: A neoadjuvant trial of cisplatin in TNBC explored specific biomarkers to identify predictors of response and found decreased BRCA1 expression may identify subsets of TNBCs that are cis platin sensitive.